Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (10): 1060-1065.doi: 10.3969/j.issn.1000-6621.2018.10.006
• Editorial • Previous Articles Next Articles
Yan HU1,Jie LIU1,(),Jing SHEN1,Da-mian ZHU1,Xin FENG1,Lin CHEN1,Jian ZHAN1,Xi-chao OU2,Yang ZHOU2,Yan-lin ZHAO2,()
Received:
2018-07-13
Online:
2018-10-10
Published:
2018-10-18
Contact:
Jie LIU,Yan-lin ZHAO
E-mail:805722291@qq.com;zhaoyl@chinacdc.cn
Yan HU,Jie LIU,Jing SHEN,Da-mian ZHU,Xin FENG,Lin CHEN,Jian ZHAN,Xi-chao OU,Yang ZHOU,Yan-lin ZHAO. Prevalence and molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to fluoroquinolones in Chongqing[J]. Chinese Journal of Antituberculosis, 2018, 40(10): 1060-1065. doi: 10.3969/j.issn.1000-6621.2018.10.006
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.10.006
药物 | 不同MIC值(μg/ml)的菌株数 | 临界 浓度 (μg/ml) | 耐药菌株[株数(率,%)] | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
≤0.31 | 0.063 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 初治 (84株) | 复治 (145株) | 合计 (229株) | χ2值 | P值 | |||
Ofx | 0 | 1 | 11 | 52 | 47 | 12 | 12 | 34 | 44 | 10 | 6 | 2.0 | 29(34.5)abc | 65(44.8)ghi | 94(41.0) | 2.334 | 0.127 | |
Lfx | 0 | 4 | 48 | 57 | 10 | 10 | 28 | 44 | 17 | 8 | 3 | 2.0 | 22(26.2)de | 50(34.5)jk | 72(31.4) | 1.697 | 0.193 | |
Mfx | 8 | 46 | 54 | 16 | 35 | 23 | 27 | 15 | 4 | 1 | 0 | 0.5 | 22(26.2)f | 48(33.1)l | 70(30.6) | 1.198 | 0.274 | |
Gfx | 56 | 49 | 21 | 26 | 31 | 31 | 5 | 8 | 2 | 0 | 0 | 0.5 | 15(17.9) | 31(21.4) | 46(20.1) | 0.411 | 0.521 |
耐药表型 | gyrA基因QRDR 区突变 | gyrB基因QRDR 区突变 | 突变菌株 [株数(率,%)] | MIC (μg/ml) | |||
---|---|---|---|---|---|---|---|
Ofx | Lfx | Mfx | Gfx | ||||
FQs耐药a(94株) | Gly88Cys | 1(1.1) | 8.0 | 4.0 | 1.0 | 0.5 | |
Asp89Asn | 1(1.1) | 4.0 | 2.0 | 2.0 | 0.5 | ||
Ala90Val | 16(17.0) | 4.0~8.0 | 2.0~4.0 | 0.25~1.0 | 0.125~0.5 | ||
Ser91Pro | 2(2.1) | 4.0 | 2.0~4.0 | 0.5~1.0 | 0.5~1.0 | ||
Asp94Asn | 7(7.4) | 4.0~8.0 | 2.0~8.0 | 0.25~4.0 | 0.125~1.0 | ||
Asp94His | 1(1.1) | 8.0 | 4.0 | 2.0 | 1.0 | ||
Asp94Ala | 5(5.3) | 4.0 | 2.0~4.0 | 0.5~1.0 | 0.125~0.5 | ||
Asp94Gly | 30(31.9) | 4.0~16.0 | 4.0~8.0 | 1.0~4.0 | 0.25~2.0 | ||
Asp94Tyr | 2(2.1) | 8.0~16.0 | 4.0~8.0 | 2.0~4.0 | 1.0~2.0 | ||
Asp94Ala&Ala90Val | 4(4.3) | 16.0~32.0 | 16.0~32.0 | 4.0~8.0 | 4.0~8.0 | ||
Asp94Ala&Ser91Pro | 1(1.1) | 16.0 | 16.0 | 8.0 | 4.0 | ||
Asp94Gly&Ala74Ser | 2(2.1) | 16.0 | 16.0 | 4.0~8.0 | 4.0 | ||
Gly512Arg | 1(1.1) | 4.0 | 4.0 | 2.0 | 1.0 | ||
Ala90Val | Asp461Asn | 3(3.2) | 16.0~32.0 | 8.0~32.0 | 2.0~4.0 | 1.0~4.0 | |
Asp94Gly | Ala504Thr | 1(1.1) | 16.0 | 16.0 | 8.0 | 4.0 | |
Asp94Gly | Ala504Val | 1(1.1) | 32.0 | 16.0 | 16.0 | 8.0 | |
Asp94Ala | Gly512Arg | 1(1.1) | 8.0 | 4.0 | 1.0 | 0.5 | |
Asp94Gly | Gly512Arg | 1(1.1) | 8.0 | 4.0 | 1.0 | 1.0 | |
Ala90Val | Gly512Arg | 1(1.1) | 4.0 | 2.0 | 0.25 | 0.5 | |
Asp94Asn | Val496Val | 1(1.1) | 16.0 | 8.0 | 2.0 | 1.0 | |
合计 | 82(87.2) | 4.0~32.0 | 2.0~32.0 | 0.25~16.0 | 0.125~8.0 | ||
FQs敏感b(135株) | Asp94Ala | 3(2.2) | 0.5~2.0 | 0.25~1.0 | 0.125~0.5 | 0.063~0.125 | |
Ala90Val | 6(4.4) | 1.0~2.0 | 1.0~2.0 | 0.25~0.5 | 0.125~0.25 | ||
Gly88Ala | 1(0.7) | 1.0 | 0.5 | 0.5 | 0.25 | ||
Arg446Leu | 1(0.7) | 1.0 | 1.0 | 0.5 | 0.25 | ||
Asp461Asn | 4(3.0) | 1.0~2.0 | 0.5~2.0 | 0.25~0.5 | 0.125~0.5 | ||
Gly512Arg | 1(0.7) | 0.125 | 0.125 | 0.063 | 0.031 | ||
合计 | 16(11.9) | 0.125~2.0 | 0.125~2.0 | 0.063~0.5 | 0.031~0.5 |
北京型(80株) | χ2值 | P值 | 非北京型 (14株) | χ2值 | P值 | |||
---|---|---|---|---|---|---|---|---|
古代北京型 (32株) | 现代北京型 (48株) | 合计 | ||||||
gyrA基因 | 26(81.3) | 43(89.6) | 69(86.3) | 0.531 | 0.466 | 12(85.7) | 0.000 | 1.000 |
Ala74Ser | 0(0.0) | 2(4.2) | 2(2.5) | - | 0.514 | 0(0.0) | - | 1.000 |
Gly88Cys | 0(0.0) | 0(0.0) | 0(0.0) | - | - | 1(7.1) | - | 0.149 |
Asp89Asn | 1(3.1) | 0(0.0) | 1(1.3) | - | 0.400 | 0(0.0) | - | 1.000 |
Ala90Val | 8(25.0) | 13(27.1) | 21(26.3) | 0.043 | 0.836 | 3(21.4) | 0.002 | 0.961 |
Ser91Pro | 0(0.0) | 2(4.2) | 2(2.5) | - | 0.514 | 1(7.1) | - | 0.387 |
94位密码子 | 17(53.1) | 33(68.8) | 50(62.5) | 2.000 | 0.157 | 7(50.0) | 0.780 | 0.377 |
Asp94Asn | 1(3.1) | 4(8.3) | 5(6.3) | 0.222 | 0.637 | 3(21.4) | 1.846 | 0.174 |
Asp94His | 0(0.0) | 1(2.1) | 1(1.3) | - | 1.000 | 0(0.0) | - | 1.000 |
Asp94Ala | 2(6.3) | 9(18.8) | 11(13.8) | 1.585 | 0.208 | 0(0.0) | 1.052 | 0.305 |
Asp94Gly | 13(40.6) | 19(39.6) | 32(40.0) | 0.009 | 0.926 | 3(21.4) | 1.758 | 0.185 |
Asp94Tyr | 1(3.1) | 0(0.0) | 1(1.3) | - | 0.400 | 1(7.1) | - | 0.277 |
gyrB基因 | 8(25.0) | 0(0.0) | 8(10.0) | 10.700 | 0.001 | 2(14.3) | 0.000 | 0.992 |
Asp461Asn | 3(9.4) | 0(0.0) | 3(3.8) | 2.439 | 0.118 | 0(0.0) | - | 1.000 |
Gly512Arg | 4(12.5) | 0(0.0) | 4(5.0) | 3.958 | 0.047 | 0(0.0) | - | 1.000 |
Ala504Thr | 0(0.0) | 0(0.0) | 0(0.0) | - | - | 1(7.1) | - | 0.149 |
Ala504Val | 1(3.1) | 0(0.0) | 1(1.3) | - | 0.400 | 0(0.0) | - | 1.000 |
Val496Val | 0(0.0) | 0(0.0) | 0(0.0) | - | - | 1(7.1) | - | 0.149 |
[1] | World Health Organization . Golobal tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[2] | Pang Y, Zhu D, Zheng H , et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis, 2017,17(1):711. |
[3] | Hu Y, Xu L, He YL , et al. Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China. Biomed Res Int, 2017,2017:4563826. |
[4] | Pang Y, Zhou Y, Zhao B , et al. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS One, 2012,7(3):e32976. |
[5] | Zhang Z, Pang Y, Wang Y , et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidmg-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents, 2014,43(3):231-235. |
[6] | Parwati I, van Crevel R, van Soolingen D . Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis, 2010,10(2):103-111. |
[7] | Nosova EY, Bukatina AA, Isaeva YD , et al. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J Med Microbiol, 2013,62(Pt 1):108-113. |
[8] |
World Health Organization . Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization, 2008.
URL pmid: 26290924 |
[9] |
Yang C, Luo T, Sun G , et al. Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin Infect Dis, 2012,55(9):1179-1187.
doi: 10.1093/cid/cis670 |
[10] |
张治国, 吴进凤, 王莉 , 等. 北京市昌平地区2011—2015年结核分枝杆菌的流行特征. 中华流行病学杂志, 2017,38(9):1236-1240.
doi: 10.3760/cma.j.issn.0254-6450.2017.09.019 URL |
[11] | Mestre O, Luo T, Dos Vultos T , et al. Phylogeny of Mycobacterium tuberculosis Beijing strains constructed from polymorphisms in genes involved in DNA replication, recombination and repair. PLoS One, 2011,6(1):e16020. |
[12] |
Luo T, Jiang L, Sun W , et al. Multiplex real-time PCR mel-ting curve assay to detect drug-resistant mutations of Mycobacterium tuberculosis. J Clin Microbiol, 2011,49(9):3132-3138.
doi: 10.1128/JCM.02046-10 |
[13] | Javaid A, Hasan R, Zafar A , et al. Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan. Int J Tuberc Lung Dis, 2017,21(3):303-308. |
[14] | Kuo CY, Wang WH, Huang CH , et al. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment. J Microbiol Immunol Infect, 2018,51(1):88-93. |
[15] | Zhang Z, Lu J, Wang Y , et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother, 2014,58(1):364-369. |
[16] |
Devasia R, Blackman A, Eden S , et al. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol, 2012,50(4):1390-1396.
doi: 10.1128/JCM.05286-11 |
[17] | Chien JY, Chiu WY, Chien ST , et al. Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother, 2016,60(4):2090-2096. |
[18] |
Yuan X, Zhang T, Kawakami K , et al. Molecular characte-rization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. J Clin Microbiol, 2012,50(7):2404-2413.
doi: 10.1128/JCM.06860-11 |
[19] | Cui Z, Wang J, Lu J , et al. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis, 2011,11:78. |
[20] | 王胜芬, 周杨, 逄宇 等. 结核分枝杆菌北京基因型菌株的流行特征及其与耐药的关系. 中国防痨杂志, 2015,37(8):836-842. |
[21] | 李妍, 曾小红, 杨健 , 等. 陕西省87株耐药结核分枝杆菌寡核苷酸基因分型和耐药性分析. 现代预防医学, 2018,45(9):1679-1683. |
[22] | 罗东, 刘涛, 熊光初 . 等. 江西省MDR-TB的MIRU-VNTR分型研究. 中国病原生物学杂志, 2018,13(3):217-225. |
[1] | Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 761-768. |
[2] | YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806. |
[3] | ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813. |
[4] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[5] | DU Wei-xin, WEI Fen, LU Jin-biao, ZHAO Ai-hua, PU Jiang, WANG Guo-zhi, XU Miao. Preliminary establishment of national reference of the freeze-dried recombinant Mycobacterium tuberculosis allergen for the bulk potency evaluation [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 826-831. |
[6] | QU Meng-jin, LIANG Zheng-min, WANG Yuan-zhi, ZHOU Xiang-mei. Research progress of carbohydrate metabolism of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 874-879. |
[7] | SONG Yi-meng, LI Yuan-chun, HE Wen-cong, HE Ping, BAO Jing-jing, LIU Chun-fa, LIU Dong-xin, WANG Xin-yang, ZHAO Yan-lin, LI Yan-ming. Cost analysis of fluorescence PCR probe melting curve technique for the detection of Mycobacterium tuberculosis resistance in China [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 712-717. |
[8] | ZHANG Jie, REN Yi-xuan, PAN Li-ping, ZHANG Zong-de. Application of whole genome sequencing in research of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 737-740. |
[9] | LI Xin-na, SHEN Xin-xin, WANG Rui-bai, DUAN Su-xia, ZHANG Rui-qing, WANG Rui-huan, BAI Xue-ding, FAN Guo-hao, WANG Jin-rong, GAO Yuan, CHEN Zi-wei, MA Xue-jun. Application value of probe-directed recombinase amplification assay in detecting MTB rpoB gene mutation [J]. Chinese Journal of Antituberculosis, 2020, 42(5): 481-488. |
[10] | ZHANG Xing,WANG Feng-ming,LYU Xu-feng,HUA Tian-qi,ZHANG Xue-jun,JIANG Jing-yi,DING Chen-li,ZHU Wei,XIA Guo-dong,JI Jun-min,ZHAO Fei. Analysis of influencing factors of Mycobacterium tuberculosis infection in HIV/AIDS patients [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 360-365. |
[11] | ZHAO Jiao-jie,FU Lei,WANG Bin,ZHANG Lei,HU Ming-hao,LU Yu. Establishment and application of pharmacodynamics and pharmacokinetics model in vitro [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 372-379. |
[12] | YANG Han,YANG Jing-fen,WU Hao,CUI Xiao-li,DANG Li-yun. Value of MicroDST test in detecting sensitivity of first-line anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2020, 42(4): 380-384. |
[13] | CHEN Yan-mei,HUANG Xin-chun,SUN Qi,ZHANG Chen-chen,WEN Wen-pei,CHEN Liang. Analysis of drug resistance in patients with smear-negative and culture-positive pulmonary tuberculosis in Guangdong province in 2016 [J]. Chinese Journal of Antituberculosis, 2020, 42(3): 272-275. |
[14] | SUN Jin-xia,ZHANG Qing-wen,LI Yin-hong,JIANG Xin. Study of autophagy induced by myricetin in MTB infected macrophages through PI3K/Akt/mTOR signaling pathway [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 101-107. |
[15] | LIU Bin-bin,GONG Dao-fang,CHEN Zhen-hua,GUO Jing-wei,YU Yan-yan,LIU Feng-ping,OU-Yang hui,TAN Yun-hong. Comparative study on detection rate and detection cost of Mycobacterium tuberculosis complex by three laboratory diagnostic techniques [J]. Chinese Journal of Antituberculosis, 2020, 42(2): 143-148. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||